Titre : Épilepsies myocloniques

Épilepsies myocloniques : Questions médicales fréquentes

Termes MeSH sélectionnés :

Complement Activation
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Épilepsies myocloniques : Questions médicales les plus fréquentes", "headline": "Épilepsies myocloniques : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Épilepsies myocloniques : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-27", "dateModified": "2025-04-23", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Épilepsies myocloniques" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Syndromes épileptiques", "url": "https://questionsmedicales.fr/mesh/D000073376", "about": { "@type": "MedicalCondition", "name": "Syndromes épileptiques", "code": { "@type": "MedicalCode", "code": "D000073376", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C10.228.140.490.493" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Épilepsies myocloniques progressives", "alternateName": "Myoclonic Epilepsies, Progressive", "url": "https://questionsmedicales.fr/mesh/D020191", "about": { "@type": "MedicalCondition", "name": "Épilepsies myocloniques progressives", "code": { "@type": "MedicalCode", "code": "D020191", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C10.228.140.490.493.063.650" } } }, { "@type": "MedicalWebPage", "name": "Épilepsie myoclonique juvénile", "alternateName": "Myoclonic Epilepsy, Juvenile", "url": "https://questionsmedicales.fr/mesh/D020190", "about": { "@type": "MedicalCondition", "name": "Épilepsie myoclonique juvénile", "code": { "@type": "MedicalCode", "code": "D020190", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C10.228.140.490.493.063.670" } } } ], "about": { "@type": "MedicalCondition", "name": "Épilepsies myocloniques", "alternateName": "Epilepsies, Myoclonic", "code": { "@type": "MedicalCode", "code": "D004831", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Pasquale Striano", "url": "https://questionsmedicales.fr/author/Pasquale%20Striano", "affiliation": { "@type": "Organization", "name": "IRCCS Istituto \"Giannina Gaslini\", Genova, Italy; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Genova, Italy." } }, { "@type": "Person", "name": "Marte Syvertsen", "url": "https://questionsmedicales.fr/author/Marte%20Syvertsen", "affiliation": { "@type": "Organization", "name": "Department of Neurology, Drammen Hospital, Vestre Viken Health Trust, Oslo, Norway." } }, { "@type": "Person", "name": "Deb K Pal", "url": "https://questionsmedicales.fr/author/Deb%20K%20Pal", "affiliation": { "@type": "Organization", "name": "Department of Basic & Clinical Neurosciences, Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK." } }, { "@type": "Person", "name": "None None", "url": "https://questionsmedicales.fr/author/None%20None", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Jeanette Koht", "url": "https://questionsmedicales.fr/author/Jeanette%20Koht", "affiliation": { "@type": "Organization", "name": "Department of Neurology, Drammen Hospital, Vestre Viken Health Trust, Oslo, Norway." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Complement-Mediated Two-Step NETosis: Serum-Induced Complement Activation and Calcium Influx Generate NADPH Oxidase-Dependent NETs in Serum-Free Conditions.", "datePublished": "2024-09-05", "url": "https://questionsmedicales.fr/article/39273570", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ijms25179625" } }, { "@type": "ScholarlyArticle", "name": "Increased retinal drusen in IgA glomerulonephritis are further evidence for complement activation in disease pathogenesis.", "datePublished": "2022-10-31", "url": "https://questionsmedicales.fr/article/36316518", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-022-21386-y" } }, { "@type": "ScholarlyArticle", "name": "Association between circulatory complement activation and hypertensive renal damage: a case-control study.", "datePublished": "2024-06-14", "url": "https://questionsmedicales.fr/article/38874150", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/0886022X.2024.2365396" } }, { "@type": "ScholarlyArticle", "name": "Cooperation of Complement MASP-1 with Other Proinflammatory Factors to Enhance the Activation of Endothelial Cells.", "datePublished": "2023-05-24", "url": "https://questionsmedicales.fr/article/37298134", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ijms24119181" } }, { "@type": "ScholarlyArticle", "name": "Application of KU812 cells for assessing complement activation related effects by nano(bio)materials.", "datePublished": "2023-05-09", "url": "https://questionsmedicales.fr/article/37167727", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.biopha.2023.114841" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Maladies du système nerveux", "item": "https://questionsmedicales.fr/mesh/D009422" }, { "@type": "ListItem", "position": 3, "name": "Maladies du système nerveux central", "item": "https://questionsmedicales.fr/mesh/D002493" }, { "@type": "ListItem", "position": 4, "name": "Encéphalopathies", "item": "https://questionsmedicales.fr/mesh/D001927" }, { "@type": "ListItem", "position": 5, "name": "Épilepsie", "item": "https://questionsmedicales.fr/mesh/D004827" }, { "@type": "ListItem", "position": 6, "name": "Syndromes épileptiques", "item": "https://questionsmedicales.fr/mesh/D000073376" }, { "@type": "ListItem", "position": 7, "name": "Épilepsies myocloniques", "item": "https://questionsmedicales.fr/mesh/D004831" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Épilepsies myocloniques - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Épilepsies myocloniques", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-12", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Épilepsies myocloniques", "description": "Comment diagnostiquer une épilepsie myoclonique ?\nQuels tests sont utilisés pour le diagnostic ?\nQuels signes cliniques indiquent une épilepsie myoclonique ?\nL'épilepsie myoclonique est-elle héréditaire ?\nQuel rôle joue l'EEG dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=Complement+Activation&page=4#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Épilepsies myocloniques", "description": "Quels sont les symptômes principaux ?\nLes myoclonies sont-elles douloureuses ?\nPeut-on avoir des crises sans myoclonies ?\nLes symptômes varient-ils d'une personne à l'autre ?\nLes crises peuvent-elles survenir la nuit ?", "url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=Complement+Activation&page=4#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Épilepsies myocloniques", "description": "Peut-on prévenir les crises myocloniques ?\nQuels déclencheurs sont à éviter ?\nL'éducation est-elle importante pour la prévention ?\nLe suivi médical est-il essentiel ?\nLes activités physiques sont-elles sûres ?", "url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=Complement+Activation&page=4#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Épilepsies myocloniques", "description": "Quels médicaments sont utilisés pour traiter ?\nY a-t-il des traitements non médicamenteux ?\nComment évaluer l'efficacité du traitement ?\nLes traitements sont-ils à vie ?\nQuels effets secondaires des médicaments ?", "url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=Complement+Activation&page=4#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Épilepsies myocloniques", "description": "Quelles complications peuvent survenir ?\nL'épilepsie myoclonique peut-elle affecter la vie quotidienne ?\nY a-t-il un risque accru de dépression ?\nLes crises peuvent-elles entraîner des accidents ?\nComment gérer les complications psychologiques ?", "url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=Complement+Activation&page=4#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Épilepsies myocloniques", "description": "Quels sont les facteurs de risque connus ?\nL'âge influence-t-il le risque d'épilepsie myoclonique ?\nLes troubles neurologiques augmentent-ils le risque ?\nLe stress est-il un facteur de risque ?\nLes infections cérébrales sont-elles un risque ?", "url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=Complement+Activation&page=4#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une épilepsie myoclonique ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'historique médical, l'examen neurologique et l'EEG." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "L'EEG, l'IRM cérébrale et des tests sanguins peuvent être utilisés." } }, { "@type": "Question", "name": "Quels signes cliniques indiquent une épilepsie myoclonique ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des secousses musculaires rapides, souvent sans perte de conscience, sont typiques." } }, { "@type": "Question", "name": "L'épilepsie myoclonique est-elle héréditaire ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Certaines formes peuvent être héréditaires, nécessitant une évaluation familiale." } }, { "@type": "Question", "name": "Quel rôle joue l'EEG dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'EEG aide à détecter les anomalies électriques typiques des épilepsies myocloniques." } }, { "@type": "Question", "name": "Quels sont les symptômes principaux ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des myoclonies, des crises généralisées et parfois des absences." } }, { "@type": "Question", "name": "Les myoclonies sont-elles douloureuses ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Les myoclonies ne sont généralement pas douloureuses, mais peuvent être gênantes." } }, { "@type": "Question", "name": "Peut-on avoir des crises sans myoclonies ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines personnes peuvent avoir des crises généralisées sans myoclonies." } }, { "@type": "Question", "name": "Les symptômes varient-ils d'une personne à l'autre ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'intensité et la fréquence des symptômes peuvent varier considérablement." } }, { "@type": "Question", "name": "Les crises peuvent-elles survenir la nuit ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des crises myocloniques peuvent survenir pendant le sommeil." } }, { "@type": "Question", "name": "Peut-on prévenir les crises myocloniques ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention passe par un traitement adéquat et l'évitement des déclencheurs." } }, { "@type": "Question", "name": "Quels déclencheurs sont à éviter ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Le stress, la fatigue, et la consommation d'alcool peuvent déclencher des crises." } }, { "@type": "Question", "name": "L'éducation est-elle importante pour la prévention ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'éducation sur la maladie aide les patients à mieux gérer leur condition." } }, { "@type": "Question", "name": "Le suivi médical est-il essentiel ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Un suivi régulier permet d'ajuster le traitement et de surveiller les symptômes." } }, { "@type": "Question", "name": "Les activités physiques sont-elles sûres ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Certaines activités peuvent être sûres, mais il faut éviter les sports à risque." } }, { "@type": "Question", "name": "Quels médicaments sont utilisés pour traiter ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les anticonvulsivants comme le valproate et le lamotrigine sont couramment prescrits." } }, { "@type": "Question", "name": "Y a-t-il des traitements non médicamenteux ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Des approches comme la thérapie comportementale et la diététique peuvent aider." } }, { "@type": "Question", "name": "Comment évaluer l'efficacité du traitement ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité est évaluée par la réduction des crises et les effets secondaires." } }, { "@type": "Question", "name": "Les traitements sont-ils à vie ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Souvent, le traitement est à long terme, mais certains peuvent réduire ou arrêter." } }, { "@type": "Question", "name": "Quels effets secondaires des médicaments ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires peuvent inclure fatigue, vertiges et troubles gastro-intestinaux." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des blessures dues aux crises et des troubles psychologiques." } }, { "@type": "Question", "name": "L'épilepsie myoclonique peut-elle affecter la vie quotidienne ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut impacter la vie sociale, professionnelle et la qualité de vie." } }, { "@type": "Question", "name": "Y a-t-il un risque accru de dépression ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes épileptiques ont un risque plus élevé de dépression et d'anxiété." } }, { "@type": "Question", "name": "Les crises peuvent-elles entraîner des accidents ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les crises peuvent provoquer des accidents, notamment lors de la conduite." } }, { "@type": "Question", "name": "Comment gérer les complications psychologiques ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Un soutien psychologique et des thérapies adaptées peuvent aider à gérer ces complications." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque connus ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux, les traumatismes crâniens et certaines infections sont des facteurs." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque d'épilepsie myoclonique ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'épilepsie myoclonique peut débuter à tout âge, mais souvent dans l'enfance ou l'adolescence." } }, { "@type": "Question", "name": "Les troubles neurologiques augmentent-ils le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, d'autres troubles neurologiques peuvent augmenter le risque d'épilepsie myoclonique." } }, { "@type": "Question", "name": "Le stress est-il un facteur de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress peut déclencher des crises chez les personnes prédisposées." } }, { "@type": "Question", "name": "Les infections cérébrales sont-elles un risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections, comme la méningite, peuvent augmenter le risque d'épilepsie." } } ] } ] }

Sources (10000 au total)

Complement-Mediated Two-Step NETosis: Serum-Induced Complement Activation and Calcium Influx Generate NADPH Oxidase-Dependent NETs in Serum-Free Conditions.

The complement system and neutrophils play crucial roles in innate immunity. Neutrophils release neutrophil extracellular traps (NETs), which are composed of decondensed DNA entangled with granular co...

Association between circulatory complement activation and hypertensive renal damage: a case-control study.

The aim of this study was to investigate the potential importance of complement system activation, with particular emphasis on the complement alternative pathway (AP), in the pathogenesis of hypertens... Serum complement C3, complement Factor H (CFH) and AP activation were assessed in 66 participants with established essential hypertension with renal damage (RD). Fifty-nine patients with age- and sex-... Our study revealed that C3 and AP50 continuously increased from normal to NRD to RD (... Abnormal activation of complement, particularly complement AP, may be a risk factor for the development and progression of hypertensive renal damage....

Pre-eclampsia is associated with complement pathway activation in the maternal and fetal circulation, and placental tissue.

Pre-eclampsia (PE) is a leading cause of obstetric morbidity, with no definitive therapy other than delivery. We aimed to compare complement markers in maternal and fetal circulation, and placental ti... Maternal and umbilical cord blood was tested for iC3b, C3, C4, properdin, Ba and C5b-9, and placental tissue for C3d, C4d, C9 and C1q, from women with PE (n = 34) and healthy pregnant controls (n = 33... Complement concentrations in maternal and umbilical cord blood, and placental immunohistochemical complement deposition.... Women with PE had significantly lower concentrations of properdin (mean: 4828 vs 6877 ng/ml, p < 0.001) and C4 (mean: 0.20 vs 0.31 g/l, p < 0.001), and higher Ba (median: 150 vs 113 ng/ml, p = 0.012),... Our data confirm excessive placental complement deposition associated with significant concurrent changes in maternal and fetal circulating complement biomarkers in PE. Inhibition of complement activa...

Postinjury complement C4 activation is associated with adverse outcomes and is potentially influenced by plasma resuscitation.

Complement activation after trauma promotes hemostasis but is associated with increased morbidity and mortality. However, the specific pathways and downstream mediators remain unclear. Recently, the a... Blood was collected from injured patients at a single level I trauma center enrolled in the Control of Major Bleeding after Trauma (COMBAT) randomized clinical trial. Proteomic analyses were performed... C4 activation occurred over the first 6 hours postinjury with peak activation 6 to 24 hours. Tissue hypoperfusion, defined as base deficit >10 mEq/L, and requirement for massive transfusion were assoc... C4 activation has an important inflammatory role postinjury, and FFP has the potential to augment this complement activation during resuscitation.... Prognostic/epidemiological, level III....

SARS-CoV-2 Nucleocapsid Protein Is Not Responsible for Over-Activation of Complement Lectin Pathway.

The nucleocapsid (N) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a viral structural protein that is abundant in the circulation of infected individuals. Previous publish...

Prevalence of anti-lymphocyte IgM autoantibodies driving complement activation in COVID-19 patients.

COVID-19 patients can develop autoantibodies against a variety of secreted and membrane proteins, including some expressed on lymphocytes. However, it is unclear what proportion of patients might deve... We evaluated the presence and lytic function of ALAb in the sera of a cohort of 85 COVID-19 patients (68 unvaccinated and 17 vaccinated) assigned to mild (N=63), or moderate/severe disease (N=22) grou... Compared with healthy donors (HD), patients had an increased prevalence of IgM ALAb, which was significantly higher in moderate/severe disease patients and persisted after recovery. Sera from IgM ALAb... IgM ALAb and complement activation against lymphocytes may contribute to the acute lymphopenia observed in COVID-19 patients....